Feedback PLC (AIM:FDBK) is set to participate in a pilot scheme to provide Community Diagnostic Centre (CDC) services with the Sussex Integrated Care System (ICS).
The pilot scheme, which will be conducted with the Queen Victoria Hospital NHS Foundation Trust (QVH), will use Feedback’s digital infrastructure to facilitate patient-specific pathways through the CDCs, linking both primary and secondary care settings.
The CDC programme is a £10bn programme designed to help reduce the elective care backlog facing the NHS by bringing diagnostic investigations closer to patients in community settings.The Sussex ICS is one of the UK's CDC exemplar sites.
The pilot is expected to run until March 2022 and will initially focus on delivering targeted CDC pathways in specific clinical areas such as respiratory and cardiology. It is anticipated that more pathways will be added as the pilot progresses with the ultimate aim of agreeing on contractual terms for a commercial roll-out to CDCs.
"The CDC programme sees the creation of an entirely new care setting and it needs the right digital infrastructure to ensure that it is fully integrated in order to deliver the intended system benefits and to drive down the elective care backlog. This is a once-in-a-generation opportunity to redesign care pathways and service delivery to our citizens,” said Tom Oakley, the chief executive officer of Feedback.
“We are delighted to be working with such an innovative team across QVH and the wider Sussex ICS and are proud that Bleepa will feature in one of the showcases of the CDC programme. Connecting teams across care settings and presenting clinical data to drive faster decision making is precisely what Bleepa is designed to deliver. The CDC programme is an exciting opportunity for us to demonstrate our technology at a regional level and we believe that this will lead to a number of broader opportunities for Bleepa and our supporting technologies within the CDC programme and beyond," Dr Oakley added.
Dr Ian Francis, the deputy medical director at QVH, said the Bleepa platform should enable the trust to deliver cross-regional care aligned to designated clinical pathways.
Shares in Feedback were up 6.3% at 0.85p in early trades.